Dunhill Financial’s Novo Nordisk NVO Stock Holding History

Dunhill Financial’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.8K	Hold	540	–	–	﹤0.01%	431
2025 Q4	$27.5K	Sell	540 -532	-50%	-$27.2K	0.01%	349
2025 Q3	$59.5K	Sell	1,072 -298	-22%	-$17.4K	0.02%	236
2025 Q2	$94.6K	Buy	1,370 +463	+51%	+$31.5K	0.03%	171
2025 Q1	$63K	Sell	907 -134	-13%	-$11.1K	0.03%	172
2024 Q4	$89.5K	Buy	1,041 +572	+122%	+$61.9K	0.04%	137
2024 Q3	$55.8K	Buy	469 +311	+197%	+$41.5K	0.03%	163
2024 Q2	$22.6K	Hold	158	–	–	0.01%	200
2024 Q1	$20.3K	Buy	158 +20	+14%	+$2.38K	0.02%	173
2023 Q4	$12.9K	Buy	+138	New	+$13.6K	0.01%	176

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Dunhill Financial's NVO Position: Q1 2026 in Review

Dunhill Financial held its Novo Nordisk (NVO) position steady in Q1 2026 at 540 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #431.

Dunhill Financial first reported a position in NVO in Q4 2023 and has held it in 10 quarters since. The position peaked at $94.6K in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Dunhill Financial held 540 shares of Novo Nordisk worth $19.8K as of Q1 2026.
Dunhill Financial left its Novo Nordisk share count unchanged in Q1 2026.
Novo Nordisk made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #431 holding.
Dunhill Financial first reported a position in Novo Nordisk in Q4 2023 and has held it in 10 quarters since.
Dunhill Financial's Novo Nordisk position peaked at $94.6K in Q2 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.